Company Analysis
Sign in

Karyopharm Therapeutics Inc. (KPTI)

Nasdaq: KPTI · Pharmaceutical Preparations · Newton, MA · filing with the SEC since 2010
Full chart Alerts Compare
Grade3.8
◀ Past 3.7● Present 3.6▶ Future 4.3
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Karyopharm Therapeutics Inc.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 1 in 2024 and 4 in 2023
Applications published
56
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Karyopharm Therapeutics Inc. its own name
named as the applicant on its applications, in US
0 granted
48 published
Karyopharm Therapeutics Inc. its own name
US, as the owner printed on each patent
39 granted
8 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,479,806Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XPO1 inhibitorsOrganic fine chemistryKaryopharm Therapeutics Inc.
Jul 29, 202512,371,420Polymorphs of SelinexorPharmaceuticalsKaryopharm Therapeutics Inc.
Jun 17, 202512,331,040Substituted benzofuranyl and benzoxazolyl compounds and uses thereofPharmaceuticalsKaryopharm Therapeutics Inc.
Jun 3, 202512,318,386Combination of XPO1 inhibitors and second agents for the treatment of prostate cancerPharmaceuticalsKaryopharm Therapeutics Inc.
May 6, 202512,291,508Hydrazide containing nuclear transport modulators and uses thereofPharmaceuticalsKaryopharm Therapeutics Inc.
Apr 2, 202411,945,794Nuclear transport modulators and uses thereofPharmaceuticalsKaryopharm Therapeutics Inc.
Nov 7, 202311,807,629Polymorphs of SelinexorPharmaceuticalsKaryopharm Therapeutics Inc.
Oct 17, 202311,787,771Hydrazide containing nuclear transport modulators and uses thereofPharmaceuticalsKaryopharm Therapeutics Inc.
Sep 12, 202311,753,401Polymorphs of SelinexorPharmaceuticalsKaryopharm Therapeutics Inc.
Sep 5, 202311,746,102Polymorphs of selinexorPharmaceuticalsKaryopharm Therapeutics Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Feb 20, 20252025/0059158NUCLEAR TRANSPORT MODULATORS AND USES THEREOFPharmaceuticalsKaryopharm Therapeutics Inc.
Nov 14, 20242024/0376114NUCLEAR TRANSPORT MODULATORS AND USES THEREOFOrganic fine chemistryKaryopharm Therapeutics Inc.
Aug 29, 20242024/0287041METHODS OF SYNTHESIS OF HETEROARYL DERIVATIVES OF TRIAZOLYL ACRYLAMIDES AND CRYSTALLINE FORMSPharmaceuticalsKaryopharm Therapeutics Inc.
Aug 22, 20242024/0279188HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOFPharmaceuticalsKaryopharm Therapeutics Inc. · patent 12,291,508 granted from it
Jun 27, 20242024/0208943POLYMORPHS OF SELINEXORPharmaceuticalsKaryopharm Therapeutics Inc. · patent 12,371,420 granted from it
Dec 7, 20232023/0391754CRYSTALLINE FORM OF SELINEXOROrganic fine chemistryKaryopharm Therapeutics Inc.
Aug 3, 20232023/0242517POLYMORPHS OF SELINEXORPharmaceuticalsKaryopharm Therapeutics Inc. · patent 11,746,102 granted from it
Aug 3, 20232023/0242516POLYMORPHS OF SELINEXORPharmaceuticalsKaryopharm Therapeutics Inc. · patent 11,753,401 granted from it
Aug 4, 20222022/0242832PROCESS FOR PREPARING XPO1 INHIBITORS AND INTERMEDIATES FOR USE IN THE PREPARATION OF XPO1 INHIBITORSOrganic fine chemistryKaryopharm Therapeutics Inc. · patent 12,479,806 granted from it
Jun 9, 20222022/0178927BIOMARKERS FOR SELINEXORPharmaceuticalsKaryopharm Therapeutics Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KPTI · research, not advice